Clinical Trial Update: 18F-MFBG Imaging for Evaluation of Neuroendocrine Malignancies [Phase 1, Phase 2]

View source ↗

Summary

Memorial Sloan Kettering Cancer Center completed a Phase 1/Phase 2 clinical trial evaluating the 18F-MFBG imaging agent for evaluating neuroendocrine tumors.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Tumors

Drugs mentioned

• [18F]-MFBG (18F-MFBG)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Neuroendocrine Tumors | Phase 1, Phase 2 | Status: COMPLETED